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Abstract : The long-term outcomes of patients with non-alcoholic fatty liver disease (NAFLD) treated with sodi-
um-glucose cotransporter-2 inhibitors remain indeterminate. Empagliflozin improves hyperglycemia by increas-
ing glucose excretion in the urine, and it reduces fat volume and insulin resistance. The aim of this study is to 
assess the effect of long-term empagliflozin therapy on hepatic inflammation, function and fibrosis in patients 
with NAFLD. This is a two-center retrospective observational study including patients with NAFLD complicated 
by type 2 diabetes mellitus. We retrospectively reviewed the medical records. Changes in parameters were inves-
tigated over one-year empagliflozin treatment. Twenty-four patients treated with empagliflozin were evaluated. 
Weight, body mass index, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpepti-
dase, fasting plasma glucose, hemoglobin A1c, serum insulin and homeostasis model assessment insulin resis-
tance significantly decreased during treatment (p < 0.05). Albumin-bilirubin (ALBI) score, a marker of hepatic 
function, was significantly improved (p < 0.01). The FIB-4 index and Mac-2 Binding Protein Glucosylation Isomer, 
markers of hepatic fibrosis, significantly improved (p < 0.01). One-year empagliflozin treatment of patients with 
NAFLD complicated by type 2 diabetes mellitus significantly improves markers of hepatic inflammation, func-
tion and fibrosis. J. Med. Invest. 67 : 280-284, August, 2020
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INTRODUCTION
 
Non-alcoholic fatty liver disease (NAFLD) is a major compli-
cation of type 2 diabetes mellitus. NAFLD is a hepatic man-
ifestation of insulin resistance and metabolic syndrome, and 
frequently complicates metabolic diseases such as diabetes, 
dyslipidemia, obesity and hypertension. NAFLD is grossly 
classified as non-alcoholic fatty liver (NAFL) and non-alcoholic 
steatohepatitis (NASH). The former has only fat deposition, and 
the latter is characterized by fibrosis due to recurrent necrosis 
and inflammation (1). NASH is a major risk factor for the de-
velopment of cirrhosis and hepatocellular carcinoma. The prev-
alence of NASH is about 3-5% worldwide and 1-2% in Japan (1, 
2). In subjects with type 2 diabetes mellitus, a high prevalence 
of NAFLD (65%) and NASH (7%) were reported (3), and type 2 
diabetes and obesity are independent predictors of NASH (4). 
Therefore, controlling the inflammation and fibrosis associated 
with NAFLD in patients with type 2 diabetes is important to 
prevent the development of cirrhosis and hepatocellular carcino-
ma. Since Japanese people are more prone to develop fatty liver 
than non-Hispanic whites in the United States even in people 
with a slightly elevated body mass index (BMI) (5), the therapeu-
tic strategy for Japanese people with NAFLD is quite important.
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) in-
hibitor, improves hyperglycemia by increasing glucose excretion 
in the urine. It was also reported to reduce fat volume and 
improve insulin resistance (6, 7). In a murine model of NASH, 
empagliflozin prevented the development of NASH by decreas-
ing inflammation and collagen deposition (8). In the EMPA-REG 
OUTCOME trial, while alanine aminotransferase (ALT) was 
significantly reduced, the diagnosis of NAFLD was not estab-
lished in that study (9). It has been reported that short-term 
SGLT2 inhibitor treatment results in improvement of inflamma-
tory markers of NAFLD and fat deposition (10-12). Few studies 
reported long-term outcomes of patients with NAFLD treated 
with an SGLT2 inhibitor. The aim of this study is to assess the 
long-term effect of empagliflozin on hepatic inflammation, func-
tion and fibrosis in patients with NAFLD complicated by type 2 
diabetes mellitus. 
METHOD
Study population and inclusion
This is a two center retrospective observational study in-
cluding patients with NAFLD complicated by type 2 diabetes 
mellitus. We retrospectively reviewed their medical records 
and abstracted the following data : age, gender, smoking habits, 
alcohol consumption, combination of medications, complications, 
weight and laboratory data. 
The inclusion criteria for this study were : (1) NAFLD compli-
cated by type 2 diabetes mellitus treated with empagliflozin, (2) 
presence of hepatorenal echo contrast on abdominal ultrasound, 
(3) persistent elevation of ALT > 30 for more than three months 
before starting empagliflozin, (4) negative hepatitis B surface 
antigen and hepatitis C virus antibody, (5) normal serum immu-
noglobulin-G level, (6) alcohol consumption < 30 g / day in males 
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and < 20 g / day in females. We excluded patients with severe 
chronic kidney disease (serum creatinine > 2.5), those who 
stopped taking empagliflozin within one year or those missing 
required laboratory data. From January 2017 to August 2018, 
patients diagnosed with NAFLD complicated by type 2 diabetes 
mellitus and treated with empagliflozin at the Saiseikai Utsu-
nomiya Hospital or the Shinozaki Medical Clinic were included. 
The institutional review boards at each center approved this 
retrospective review.
Evaluation of hepatic inflammation, function and fibrosis
Although liver biopsy is the best method to evaluate the degree 
of hepatic inflammation and fibrosis, it is difficult to perform in 
routine clinical practice because of its complexity and risk of se-
rious adverse events. Hepatic inflammation was evaluated with 
serum ALT levels, a validated marker for progression of hepatic 
fibrosis in patients with NASH (13, 14). Hepatic function was 
estimated with the albumin-bilirubin (ALBI) score, calculated 
using both serum albumin and bilirubin levels and reflects in-
docyanine green retention rate at 15 min (ICG-R15) (15). The 
degree of hepatic fibrosis was estimated using the cutoff index of 
the serum Mac-2 Binding Protein Glucosylation Isomer (M2B-
PGi) that is a glycoprotein biomarker reflecting the grade of 
hepatic fibrosis and a predictor of developing hepatocellular car-
cinoma over the long-term (16-18). The FIB-4 index and NAFLD 
fibrosis score were used as markers of hepatic fibrosis (19, 20). 
The degree of insulin resistance that is closely associated with 
pathogenesis of NAFLD was evaluated with HOMA-IR (homeo-
stasis model assessment insulin resistance) (21). 
Statistical analysis 
Statistical analysis was carried out using StatFlex 7.0 soft-
ware (Artech Co., Ltd., Osaka, Japan). Differences were consid-
ered significant with p < 0.05. The chi-square goodness-of-fit test 
did not show a normal distribution of the values of clinical pa-
rameters. Changes in clinical parameters were evaluated with 
the Wilcoxon rank-sum test. Correlation was analyzed using 
Spearman’s Rank correlation coefficient.
RESULTS
Baseline characteristics
From January 2017 to August 2018, 28 patients were treated 
with empagliflozin. Twenty-four of these 28 patients were in-
cluded in the final analysis after excluding four patients for the 
following reasons : empagliflozin was stopped within one year 
because the patient did not visit the clinic (n = 2) and a lack of 
required laboratory data (n = 2). 
Characteristics of the 24 patients treated with empagliflozin 
10 mg daily for one year are shown in Table 1. More than half 
of the patients were treated with a statin drug for hypercholes-
terolemia, and there were no further additions of statins after 
starting empagliflozin. Tocopherol or ursodeoxycholic acid was 
not used during the study period. The dose of empagliflozin 
remained at 10 mg once daily for one year without dose escala-
tion. There were no dose escalations or cession of anti-diabetic 
drugs except in one patient who underwent dose escalation of 
metformin from 1500 mg to 2000 mg per day. No adverse events 
were observed. 
To understand the difference among the hepatic fibrosis mark-
ers before starting empagliflozin, we investigated the correlation 
between M2BPGi and markers of hepatic fibrosis. Significant 
positive correlations with M2BPGi were observed with the 
FIB-4 index (r = 0.691, p < 0.001) and the NAFLD fibrosis score 
(r = 0.644, p < 0.001).
Improvement of markers of hepatic inflammation, function and 
fibrosis during one-year empagliflozin treatment
Changes in clinical parameters were investigated after one-
year empagliflozin treatment (Table 2). Weight, BMI, AST, ALT 
and γ-GTP significantly decreased, and lipid parameters did not 
significantly change after one year of treatment. Diabetic mark-
ers including fasting plasma glucose (FPG), hemoglobin A1c 
(HbA1c), serum insulin and HOMA-IR significantly improved. 
Table 1.　Baseline characteristics of patients treated with empagli-
flozin 
N = 24
Age, years, mean ± standard error 57.4 ± 2.9
Gender, male, n 15 (63%)
Current Smoker, n 7 (29%)
Complications treated with medication, n
Dyslipidemia 15 (63%)
Hypertension 11 (46%)




Angiotensin II receptor blockers 9 (38%)
Metformin 8 (33%)
DPP-4 inhibitors 6 (25%)
Pioglitazone 3 (13%)
Bezafibrate 2 (8%)
GLP-1 analog 1 (4%)
Ezetimibe 1 (4%)
DPP-4 : dipeptidyl peptidase-4, GLP-1 : glucagon-liken peptide-1
Table 2.　Changes during one-year empagliflozin therapy
Before One-year p-value
Weight, kg, mean ± SE 82.2 ± 4.7 78.8 ± 4.5 < 0.001
Body mass index 30.3 ± 1.3 28.9 ± 1.2 < 0.001
Platelet, x104 / μL 22.1 ± 1.4 22.4 ± 1.3 0.334
AST, U / L 45.7 ± 4.2 33.4 ± 3.7 < 0.001
ALT, U / L 53.7 ± 4.5 35.3 ± 4.5 < 0.001
ALP, U / L 226.9 ± 11.9 216.5 ± 14.6 0.072
γ-GTP, U / L 72.3 ± 8.7 50.5 ± 6.4 < 0.001
Total bilirubin, mg / dL 0.85 ± 0.07 0.78 ± 0.08 0.095
LDL cholesterol, mg / dL 104.8 ± 7.1 98.5 ± 5.5 0.481
HDL cholesterol, mg / dL 46.6 ± 2.5 49.6 ± 2.3 0.087
Triglyceride, mg / dL 256.9 ± 68.6 244.2 ± 43.9 0.404
Serum albumin, g / dL 4.3 ± 0.1 4.5 ± 0.1 0.002
Estimated GFR, ml / min / 1.73m2 81.6 ± 3.2 79.0 ± 3.0 0.092
Fasting plasma glucose, mg / dL 149.9 ± 9.7 115.2 ± 5.0 < 0.001
Serum insulin, μU / mL 18.0 ± 4.0 11.8 ± 2.3 0.009
HbA1c, % 7.3 ± 0.2 6.7 ± 0.1 < 0.001
HOMA-IR 6.5 ± 1.3 3.1 ± 0.5 < 0.001
SE : standard error, AST : aspartate aminotransferase, ALT : 
alanine aminotransferase, ALP : alkaline phosphatase, γ-GTP : 
γ-glutamyl transpeptidase, LDL : low density lipoprotein, HDL : 
high density lipoprotein, GFR : glomerular filtration rate, HbA1c : 
hemoglobin A1c (glycated hemoglobin), HOMA-IR : homeostasis 
model assessment insulin resistance
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The levels of markers of hepatic function and fibrosis are 
shown in Figure 1. The ALBI score, a marker of hepatic function, 
was significantly improved. Hepatic fibrosis markers including 
the FIB-4 index and M2BPGi significantly decreased at 12 
months. The NAFLD fibrosis score had a likelihood of a decre-
ment. Unlike other parameters, M2BPGi showed a significant 




This observational study demonstrates the effectiveness of a 
one-year course of empagliflozin 10 mg daily to improve markers 
of hepatic inflammation, function and fibrosis in patients with 
NAFLD complicated by type 2 diabetes mellitus. One-year em-
pagliflozin treatment improved weight, plasma glucose and in-
sulin resistance. Since the observation period in previous studies 
reporting the effectiveness of SGLT2 inhibitors on NAFLD was 
at most six months, the observation period in the present study 
is comparatively long. This is the first study demonstrating an 
improvement in markers of hepatic fibrosis due to NAFLD after 
one-year treatment with empagliflozin. 
Empagliflozin ameliorates hepatic steatosis, inflammation 
and fibrosis in a murine model of NASH and diabetes mellitus 
(8). The clinical efficacy of empagliflozin on NAFLD has been 
reported. The EMPA-REG OUTCOME trial revealed a sig-
nificant decrease in serum liver enzyme levels including AST 
and ALT in the empagliflozin-treated group compared with the 
placebo group (9). However, the diagnosis of NAFLD was not es-
tablished in the trial. The E-LIFT trial from India demonstrated 
that treatment with empagliflozin significantly reduced liver 
fat and ALT compared to placebo during a 20 week treatment 
period evaluated by MRI-derived proton density fat fraction (11). 
A randomized controlled trial from Germany reported a signif-
icant reduction of liver fat content in the empagliflozin treated 
group compared with the placebo group, and this trial did not 
show improvement in LDL cholesterol levels over 24 weeks (22). 
A single-arm pilot study with empagliflozin 25 mg daily for 
24 weeks demonstrated improvements in steatosis, ballooning 
and fibrosis seen on liver biopsy (23). The present study has the 
longest observation period in patients with NAFLD treated with 
empagliflozin.
A recent Japanese study including 20 patients with NAFLD 
complicated by type 2 diabetes mellitus treated with canagli-
flozin for one year reported a significant reduction in weight 
and ALT without improving the FIB-4 index (24). In the pres-
ent study, the FIB-4 index and M2BPGi were significantly 
improved. The FIB-4 index before starting empagliflozin in the 
present study (2.0 ± 1.4) is somewhat higher than in the canagli-
flozin study (1.2 ± 0.5) (24). The difference in the change of the 
FIB-4 index may be explained by the degree of hepatic fibrosis 
before starting treatment and / or the type of SGLT2 inhibitor. A 
recent Japanese randomized controlled trial using luseogliflozin 
versus metformin reported that patients in the luseogliflozin 
group had a significant reduction of liver fat deposition (25). 
A recent Japanese NAFLD study with luseogliflozin reported 
that there was no significant reduction of M2BPGi during 24 
weeks of treatment (26). The present study also did not show a 
significant reduction of M2BPGi at six months after starting 
empagliflozin but there was a significant reduction at one year. 
Improvement of hepatic fibrosis in patients with NAFLD may 
require at least one-year SGLT2 inhibitor treatment.
This study has several acknowledged limitations. First, this 
is a retrospective observational study without a control group, 
and the sample size is small. Second, lipid deposition in the liver 
was not evaluated using magnetic resonance. Third, the degree 
of hepatic fibrosis was not evaluated by histology but by reliable 
markers of hepatic fibrosis. Fourth, the combined use of medi-
cations for diabetes and dyslipidemia might bias these results. 
The influence of pioglitazone, a key medication for NAFLD, is 
interesting. Since only three patients used pioglitazone, formal 
assessment of its influence cannot be made. In this study, the 
NAFLD fibrosis score showed a likelihood of a decrement after 
one-year treatment, but the reduction did not reach statistical 
significance. Additional long-term observation may demonstrate 
a significant decrement in the NAFLD fibrosis score. 
In conclusion, one-year empagliflozin treatment in patients 
with NAFLD complicated by type 2 diabetes mellitus resulted 
in significantly improved markers of hepatic inflammation, 
function and fibrosis. This is the first study reporting the effect 
of empagliflozin on NAFLD during a one-year treatment period. 
Since hepatic fibrosis progresses for several years, further long-
term studies are necessary to confirm these preliminary results.
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